Inhibrx (INBX) analyst forecast and price target
Analyst forecast
Consensus of 4 analyst ratings
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| HC Wainwright & Co. | Initiated Coverage | Buy | $245.00 | Aug 24, 2026 |
| Stifel | Initiated Coverage | Buy | $150.00 | Apr 8, 2026 |
| JMP Securities | Maintained | Market Perform | — | Aug 22, 2025 |
| JMP Securities | Maintained | Market Perform | — | May 15, 2025 |
| Citizens Capital Markets | Maintained | Market Perform | — | Mar 18, 2025 |
| JMP Securities | Maintained | Market Perform | — | Jan 22, 2025 |
| JMP Securities | Initiated Coverage | Market Perform | — | Jul 23, 2024 |
Frequently asked questions
Is INBX a buy, sell, or hold?
Analysts covering Inhibrx currently average a Buy rating: 3 buy, 1 hold and 0 sell, from 4 analysts. Ratings reflect analyst opinion, not investment advice.
What is the latest analyst rating on INBX?
On Aug 24, 2026, HC Wainwright & Co. initiated coverage of Inhibrx at Buy with a price target of $245.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.